drugset

drugset / Trial / NCT01052831

Naltrexone for Impulse Control Disorders in Parkinson's Disease

NCT01052831 ↗

Phase 4 Completed 50 enrolled University of Pennsylvania Michael J. Fox Foundation for Parkinson's Research · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the effectiveness of naltrexone in reducing ICD symptoms in Parkinson's disease patients taking a dopamine agonist.

Timeline

Start: 2009-11
Primary completion: 2012-12
Completion: 2012-12

Publications

Results Papay K, Xie SX, Stern M, Hurtig H, Siderowf A, Duda JE, Minger J, Weintraub D. Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. Neurology. 2014 Aug 26;83(9):826-33. doi: 10.1212/WNL.0000000000000729. Epub 2014 Jul 18.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Naltrexone	Small molecule	50 mg	—
Comparator	Naltrexone	Small molecule	100 mg	—

Indications